Mutual of America Capital Management LLC Decreases Stock Holdings in Lantheus Holdings, Inc. $LNTH

Mutual of America Capital Management LLC lessened its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 27.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 56,154 shares of the medical equipment provider’s stock after selling 21,576 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Lantheus were worth $2,880,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of LNTH. Sector Gamma AS boosted its position in shares of Lantheus by 28.0% during the 3rd quarter. Sector Gamma AS now owns 64,403 shares of the medical equipment provider’s stock worth $3,303,000 after acquiring an additional 14,102 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Lantheus during the third quarter worth approximately $3,866,000. UNIVEST FINANCIAL Corp boosted its holdings in Lantheus by 46.0% in the third quarter. UNIVEST FINANCIAL Corp now owns 31,024 shares of the medical equipment provider’s stock valued at $1,591,000 after purchasing an additional 9,781 shares in the last quarter. Covestor Ltd increased its stake in Lantheus by 430.5% in the third quarter. Covestor Ltd now owns 1,740 shares of the medical equipment provider’s stock valued at $90,000 after purchasing an additional 1,412 shares during the last quarter. Finally, Verdence Capital Advisors LLC raised its holdings in Lantheus by 41.2% during the third quarter. Verdence Capital Advisors LLC now owns 8,145 shares of the medical equipment provider’s stock worth $418,000 after purchasing an additional 2,376 shares in the last quarter. 99.06% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the stock. The Goldman Sachs Group set a $77.00 target price on shares of Lantheus and gave the company a “neutral” rating in a research report on Wednesday, October 8th. Weiss Ratings raised Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Mizuho lifted their target price on Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Finally, Truist Financial upped their target price on Lantheus from $80.00 to $82.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. Five research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Stock Up 0.4%

LNTH opened at $66.92 on Friday. The company has a market cap of $4.44 billion, a PE ratio of 28.12 and a beta of -0.11. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. The business has a 50 day moving average price of $64.87 and a two-hundred day moving average price of $59.88. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share for the quarter, hitting the consensus estimate of $1.27. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.The firm had revenue of $384.01 million during the quarter, compared to the consensus estimate of $363.42 million. During the same period last year, the company earned $1.70 earnings per share. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. As a group, research analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.